{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:45:26Z","timestamp":1785786326691,"version":"3.56.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Twenty-seven patients receiving prolonged inpatient antibiotic therapy for a serious bacterial infection received a single dose of dalbavancin 7\u201310 days before the planned end date to facilitate earlier hospital discharge. Eighty-one percent met criteria for clinical success, 7% experienced a potential adverse event, and 182 hospital days were averted.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa293","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T15:34:52Z","timestamp":1594654492000},"source":"Crossref","is-referenced-by-count":36,"title":["Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-1460","authenticated-orcid":false,"given":"Axel A","family":"Vazquez Deida","sequence":"first","affiliation":[{"name":"Pharmacy Department, Denver Health Medical Center, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C","family":"Shihadeh","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Denver Health Medical Center, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice R","family":"Preslaski","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Denver Health Medical Center, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Wyles","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Denver Health Medical Center, Denver, Colorado, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"2020080913462462200_CIT0001","doi-asserted-by":"crossref","first-page":"e97596","DOI":"10.1371\/journal.pone.0097596","article-title":"Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections","volume":"9","author":"Lansky","year":"2014","journal-title":"PLoS One"},{"key":"2020080913462462200_CIT0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1086\/522176","article-title":"Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis","volume":"45","author":"Cooper","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020080913462462200_CIT0003","doi-asserted-by":"crossref","first-page":"e012969","DOI":"10.1161\/JAHA.119.012969","article-title":"Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016","volume":"8","author":"Kadri","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2020080913462462200_CIT0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020080913462462200_CIT0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2020080913462462200_CIT0006","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2020080913462462200_CIT0007","article-title":"Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections","author":"Marks","year":"","journal-title":"Clin Infect Dis"},{"key":"2020080913462462200_CIT0008","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020080913462462200_CIT0009","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020080913462462200_CIT0010","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2020080913462462200_CIT0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020080913462462200_CIT0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020080913462462200_CIT0013","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020080913462462200_CIT0014","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa293\/33491349\/ofaa293.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/8\/ofaa293\/33620667\/ofaa293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/8\/ofaa293\/33620667\/ofaa293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T17:46:37Z","timestamp":1596995197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa293\/5870812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa293","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,7,13]]},"article-number":"ofaa293"}}